We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+14.04%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$229M
AUM Growth
+$34.9M
Cap. Flow
+$4.27M
Cap. Flow %
1.87%
Top 10 Hldgs %
57.76%
Holding
47
New
12
Increased
9
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$14.1M
2
CI icon
Cigna
CI
+$11.8M
3
URGN icon
UroGen Pharma
URGN
+$6.62M
4
NVRO
NEVRO CORP.
NVRO
+$6.05M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.75M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.21M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.42M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.77M
4
HNGR
Hanger Inc.
HNGR
+$5.07M
5
VKTX icon
Viking Therapeutics
VKTX
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 90.43%
2 Miscellaneous 4.62%
3 Technology 3.03%
4 Industrials 1.92%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$74.1B
$22.2M 9.71%
138,000
+64,700
+88% +$11.8M
HNGR
2
DELISTED
Hanger Inc.
HNGR
$17.8M 7.78%
933,548
-255,851
-22% -$5.07M
ZBH icon
3
Zimmer Biomet
ZBH
$18.5B
$15.8M 6.9%
127,205
+20,724
+19% +$2.36M
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15M 6.57%
175,700
-77,300
-31% -$6.42M
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$13.5M 5.91%
+283,000
New +$14.1M
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.3M 4.95%
252,500
-25,150
-9% -$1.15M
WCG
7
DELISTED
Wellcare Health Plans, Inc.
WCG
$11M 4.8%
40,700
-9,300
-19% -$2.4M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$4.47B
$8.72M 3.82%
917,080
-145,420
-14% -$1.41M
ALBO
9
DELISTED
Albireo Pharma Inc
ALBO
$8.69M 3.8%
269,836
-310
-0.1% -$8.35K
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$8.05M 3.52%
+128,765
New +$6.05M
EFOR
11
Everforth Inc
EFOR
$1.33B
$6.93M 3.03%
109,116
+21,416
+24% +$1.34M
ASMB icon
12
Assembly Biosciences
ASMB
$519M
$6.19M 2.71%
26,201
+3,206
+14% +$812K
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
$6.19M 2.71%
249,389
+189,289
+315% +$4.75M
URGN icon
14
UroGen Pharma
URGN
$2.13B
$5.83M 2.55%
+157,862
New +$6.62M
ALDX icon
15
Aldeyra Therapeutics
ALDX
$82.6M
$5.27M 2.3%
583,300
+178,837
+44% +$1.52M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$12.5B
$5.1M 2.23%
57,384
-45,616
-44% -$4.23M
EXAS
17
PUT
DELISTED
Exact Sciences
EXAS
$4.72M 2.07%
+54,500
New +$4.64M
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.65M 2.03%
933,876
-4,024
-0.4% -$19.8K
WAGE
19
DELISTED
WageWorks, Inc.
WAGE
$4.38M 1.92%
+115,926
New +$3.78M
NVRO
20
CALL
DELISTED
NEVRO CORP.
NVRO
$4.38M 1.91%
+70,000
New +$3.29M
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.2M 1.84%
61,442
-2,407
-4% -$154K
CNC icon
22
Centene
CNC
$32.6B
$4.16M 1.82%
78,400
+28,400
+57% +$1.72M
TPST icon
23
Tempest Therapeutics
TPST
$20M
$4.06M 1.78%
1,389
+72
+5% +$159K
INDP icon
24
Indaptus Therapeutics
INDP
$428M
$3.98M 1.74%
242
-60
-20% -$1.05M
GYRE icon
25
Gyre Therapeutics
GYRE
$710M
$3.93M 1.72%
64,560
+2,307
+4% +$148K
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2019 Portfolio in Review

As of Q1 2019, Prosight Management held 47 positions worth $229M, up 18% from $194M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Prosight Management's Q1 2019 filing shows 12 new, 9 increased, 17 reduced and 9 closed positions. Its largest new stake was Bristol-Myers Squibb: 283,000 shares worth $13.5M. The largest sale was Allergan plc, an estimated $8.21M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Technology.

  • Prosight Management's largest Q1 2019 buy was Bristol-Myers Squibb: 283,000 shares worth $13.5M.
  • Prosight Management added most to Cigna in Q1 2019, an estimated $11.8M increase.
  • Prosight Management's biggest Q1 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $6.42M.
  • Prosight Management fully exited Allergan plc in Q1 2019, selling an estimated $8.21M.
  • Prosight Management's ten largest holdings make up 58% of its $229M portfolio in Q1 2019.
  • Prosight Management opened 12 new positions and closed 9 in Q1 2019.
  • Prosight Management's portfolio value rose 18% quarter-over-quarter to $229M.

Based on Prosight Management's 13F filing for Q1 2019, filed 15 May 2019.